Leukämien | ICD10: C91-C96
Sie befinden sich hier:
Studien offen zur Rekrutierung
AC220-A-U302_QuANTUM-First192 kB
A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
AMLSG 21-13147 kB
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia
AMLSG BIO17.0 kB
Registerstudie zum biologischen Erkrankungsprofil und klinischen Verlauf bei der akuten myeloischen Leukämie und verwandten Vorläufer- Neoplasien und der akuten Leukämie unklarer Linienzugehörigkeit: Das AMLSG Biology and Outcome (BiO)-Projekt
AMLSG26-16/AML-VIVA191 kB
Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy
GMALL 08/2013159 kB
Therapieoptimierung bei erwachsenen Patienten mit neu diagnostizierter akuter lymphatischer Leukämie (ALL) oder lymphoblastischem Lymphom (LBL) durch individualisierte, gezielte und intensivierte Therapie
GMALL Register48 kB
GMALL-REGISTER Nicht-interventionelle Studie mit begleitender Biomaterialbank
Pran-16-52302 kB
A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients .18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy
REACH2101 kB
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Ruxo-BEAT Studie_Myelofibrose166 kB
Ruxolitinib versus best available therapy in patients with high-risk polycytehemia vera or high-risk essential thrombocythemia
SAL-AML RegisterAML-Register und Biomaterialdatenbank der Studienallianz Leukämie (SAL)
TUD-2Dauno-058_DaunoDouble152 kB
Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia < 60a
TUD-DELTA1-063200 kB
A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients =65 Years of Age Not Eligible for Intensive Chemotherapy